Key facts
- It has raised $18.5M across 1 recorded rounds; the latest was Early Stage VC ($18.5M) in Nov 2025.
- Notable investors include LifeSpan Vision Ventures, MDB Capital Holdings.
- Paulex Bio has filed 1 Form D with the SEC, most recently Dec 2025 ($18.5M sold to 163 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Paulex Bio
Funding rounds
1 roundsAbout Paulex Bio
Developer of diabetes-focused biotechnology products designed to advance scientific and technological progress in diabetes management. The company conducts research and development in diabetes care, incorporates innovative scientific methods, and leverages advanced technology to address unmet medical needs, enabling healthcare providers and patients to access improved diabetes management options and contribute to the goal of a world without diabetes.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2023
- Employees
- 2
- Website
- paulexbio.com/
- Ownership
- Privately Held (backing)
Paulex Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Paulex Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Paulex Bio in its N-PORT filings yet. We sweep new filings monthly.